


Product Name : Oprozomib
Cat. No. : PC-42896
CAS No. : 935888-69-0
Molecular Formula : C₂₅H₃₂N₄O₇S
Molecular Weight : 532.6092
Target : Proteasome
Solubility : DMSO: ≥ 50 mg/mL



Biological Activity

Oprozomib (ONX-0912;PR-047) is a potent, orally bioavailable proteasome inhibitor that inhibits chymotrypsin-like (CT-L) activity of 20S proteasome β5/LMP7 with IC₅₀ of 36/82 nM; triggers apoptosis in MM cells, associated with PARP cleavage and caspase activation, causes in vitro and in vivo cytotoxicity in multiple myeloma, also enhances anti-MM activity of bortezomib, lenalidomide dexamethasone, or pan-histone deacetylase inhibitor.

Blood Cancer
Phase 2 Clinical

References

Verbrugge SE, et al. J Pharmacol Exp Ther. 2012 Apr;341(1):174-82.

Chauhan D, et al. Blood. 2010 Dec 2;116(23):4906-15.

Zhou HJ, et al. J Med Chem. 2009 May 14;52(9):3028-38.

Hurchla MA, et al. Leukemia. 2013 Feb;27(2):430-40.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com